Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: A cohort study by Bansal, Nisha et al.
RESEARCH ARTICLE Open Access
Potential role of differential medication use in
explaining excess risk of cardiovascular events
and death associated with chronic kidney
disease: A cohort study
Nisha Bansal
1*†, Chi-yuan Hsu
1†, Malini Chandra
2†, Carlos Iribarren
2, Stephen P Fortmann
3, Mark A Hlatky
3 and
Alan S Go
1,2†
Abstract
Background: Patients with chronic kidney disease (CKD) are less likely to receive cardiovascular medications. It is
unclear whether differential cardiovascular drug use explains, in part, the excess risk of cardiovascular events and
death in patients with CKD and coronary heart disease (CHD).
Methods: The ADVANCE Study enrolled patients with new onset CHD (2001-2003) who did (N = 159) or did not
have (N = 1088) CKD at entry. The MDRD equation was used to estimate glomerular filtration rate (eGFR) using
calibrated serum creatinine measurements. Patient characteristics, medication use, cardiovascular events and death
were ascertained from self-report and health plan electronic databases through December 2008.
Results: Post-CHD event ACE inhibitor use was lower (medication possession ratio 0.50 vs. 0.58, P = 0.03) and
calcium channel blocker use higher (0.47 vs. 0.38, P = 0.06) in CKD vs. non-CKD patients, respectively. Incidence of
cardiovascular events and death was higher in CKD vs. non-CKD patients (13.9 vs. 11.5 per 100 person-years, P <
0.001, respectively). After adjustment for patient characteristics, the rate of cardiovascular events and death was
increased for eGFR 45-59 ml/min/1.73 m
2 (hazard ratio [HR] 1.47, 95% CI: 1.10 to 2.02) and eGFR < 45 ml/min/1.73
m
2 (HR 1.58, 95% CI: 1.00 to 2.50). After further adjustment for statins, b-blocker, calcium channel blocker, ACE
inhibitor/ARB use, the association was no longer significant for eGFR 45-59 ml/min/1.73 m
2 (HR 0.82, 95% CI: 0.25
to 2.66) or for eGFR < 45 ml/min/1.73 m
2 (HR 1.19, 95% CI: 0.25 to 5.58).
Conclusions: In adults with CHD, differential use of cardiovascular medications may contribute to the higher risk of
cardiovascular events and death in patients with CKD.
Background
Cardiovascular diseases remain the leading cause of
death in patients with chronic kidney disease (CKD)
[1-5]. Potential modification of cardiovascular disease
risk through pharmacological interventions is a critical
component of current care and prevention in patients
with known coronary heart disease (CHD) or at risk for
CHD.
Observational studies have shown that despite being at
high risk for CHD, many patients with CKD or end-
stage renal disease (ESRD) are less likely to receive car-
diovascular medications [6-8]. One study found that
among the 35.5% of CKD patients not taking an angio-
tensin converting enzyme (ACE) inhibitor, over half did
not have clear contraindications to ACE inhibitor use
[9]. In certain studies, CKD or ESRD patients hospita-
lized with acute myocardial infarction were less likely to
receive immediate evidence-based therapies such as
aspirin, b-blockers, ACE inhibitors, angiotensin receptor
blockers (ARBs) or lipid lowering agents [10-17].
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patients with CKD have substantial cardiovascular dis-
ease burden [18-20] and are frequently under-prescribed
beneficial cardiovascular medications, the potential
impact of cardiovascular medications exposure on recur-
rent cardiovascular events in those with CKD and
known CHD is not known. Underuseof cardioprotective
medications may be one explanation for the excess car-
diovascular morbidity in this at-risk patient population
[21]. To address this, we examined whether differential
cardiovascular drug use, specifically statins, b-blockers,
calcium channel blockers, ACE inhibitors and ARBs,
helps to explain, at least in part, the excess risk of recur-
rent cardiovascular disease events associated with CKD
in a large prospective cohort of patients with known
CHD followed longitudinally.
Methods
Study sample and study design
The source population included adults (age ≥ 20 years)
who received medical care within Kaiser Permanente of
Northern California, a large integrated healthcare deliv-
ery system providing comprehensive care to more than
30% of insured adults in the San Francisco and greater
Bay area. Previous studies have shown that the member-
ship is representative of the local surrounding and state-
wide insured adult population, with the exception of
slightly lower proportions of persons at the extremes of
age and income level [22]. Adult members of Kaiser
between the ages of 45 to 75 years with no prior history
of CHD who first presented with new symptoms of
CHD (either stable exertional angina or acute myocar-
dial infarction) between October 28, 2001 and Decem-
ber 31, 2003 were enrolled into the Atherosclerotic
Disease, VAscular functioN, and genetiC Epidemiology
(ADVANCE) Study [23]. Recruitment of study partici-
pants, exlusion and inclusion criteria into the
ADVANCE study has been described in detail previously
[23]. Institutional review boards of the collaborating
institutions at Kaiser Permanente Northern California
and Stanford University approved the study, and written
informed consent was obtained from all study
participants.
To identify cases of incident acute myocardial infarc-
tion, we identified men aged 45 to 75 years old and
women aged 55 to75 years old who had acute myocar-
dial infarction as their first presentation of clinical cor-
onary disease between October 28, 2001 through
December 31, 2003 by weekly searches of automated
laboratory for elevated cardiac enzymes and hospital dis-
charge databases for primary discharge diagnosis of
myocardial infarction (ICD-9-CM code 410). Primary
care physicians and patients were screened by telephone
interview to confirm the absence of prior diagnosed
coronary heart disease, coronary revascularization, or
ischemic symptoms more than 14 days before admission
for acute myocardial infarction. In addition, electrocar-
diograms were systematically reviewed to exclude any
patients with a prior silent Q-wave myocardial infarc-
tion. To identify cases of incident stable exertional
angina, we identified men and women aged 45 to 75
years old who had stable exertional angina as their first
presentation of clinical coronary disease during this
same time period by performing weekly searches of
automated ambulatory visit databases for new outpatient
diagnoses of angina pectoris (ICD-9-CM 413.x). Primary
treating physicians of potential participants were con-
tacted to confirm the occurrence of new onset, stable
exertional angina. Patients were similarly screened by
telephone interview to confirm the absence of prior cor-
onary heart disease and coronary revascularization. In
addition, patients had to report evidence of stable chest
pain or chest pressure reproduced by the same level of
physical exertion, lasting more than one minute and less
than 15 minutes, and responded to rest or nitroglycerin.
We conducted a parallel cohort study of participants
of ADVANCE followed from the index date of initial
CHD event until December 31, 2008 to assess differen-
tial patterns of medication use and rates of recurrent
cardiovascular events after an incident CHD event. The
exposed group included those with pre-existing chronic
kidney disease (CKD), defined as estimated glomerular
filtration rate (eGFR) < 60 ml/min/1.73 m
2. The unex-
posed, control group included participants of
ADVANCE without pre-existing CKD, and were also
followed longitudinally for the same time period.
Measurement of kidney function
Kidney function was assessed using estimated glomeru-
lar filtration rate calculated from the latest serum creati-
nine measurement prior to the index date. Estimated
glomerular filtration rate (eGFR) was estimated using
the four-variable abbreviated Modification of Diet in
Renal Disease (MDRD) Study equation [24] based on
the latest outpatient serum creatinine test result found
in health plan laboratory databases prior to the index
date [25]. Based on prior work and recent guidelines
published by the Kidney Disease: Improving Global Out-
comes (KDIGO) Committee, we staged kidney function
as (in units of ml/min/1.73 m
2): 90 to 130, 60 to 89, 45-
59, and less than 45 [18,26]. As previously described,
serum creatinine values were calibrated to the core
laboratory used to generate the MDRD estimating equa-
tion [18].
Measurement of medication use
Medication exposure was obtained from health system
pharmacy databases. Medication exposure in days was
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the end of the study period December 31, 2008. The
medication possession ratio (MPR), the number of days
of exposure to medication divided by the number of
days of follow-up from enrollment date, was calculated
for each class of medications (statins, b-blockers, cal-
cium channel blockers, ACE inhibitors, ARBs) for both
the study cohort and controls, which has been validated
in previous studies as a summary measure of possible
medication adherence [27-29]. If a patient was not pre-
scribed a particular medication class, the MPR was
assigned a value of zero.
Covariates
Data were collected on demographic characteristics, life-
style factors, cardiovascular and other medical history,
family history of coronary heart disease, systolic and dia-
stolic blood pressure, and body mass index [30]. Age at
index date was based on self-report and confirmed in
health plan databases. Patients also provided self-
reported information on gender, race/ethnicity, marital
status, employment status, annual household income,
parental and sibling history of coronary heart disease,
history of prior stroke, peripheral arterial disease, dia-
betes mellitus, hypertension, smoking status at index
date (current, former, or never), alcohol use and inten-
sity of leisure-time activity during the 12 months prior
to study visit date. The most recent outpatient systolic
and diastolic blood pressure values before index date
were obtained from ambulatory visit databases, which
have been shown to reliably reflect chronic blood pres-
sure levels in our database [31]. Body mass index (kg/
m
2) was measured at the study visit using standard
procedures.
Outcomes
The primary outcome was the occurrence of a recurrent
cardiovascular disease event (i.e., hospitalization for
acute myocardial infarction, angina, coronary artery
bypass graft surgery, percutaneous coronary interven-
tion, peripheral arterial disease, revascularization or
stroke) identified from hospital discharge diagnosis and
billing claims databases using validated International
Classification of Diseases, Ninth Edition (ICD-9) codes
as well as deaths identified from health plan administra-
tive databases, Social Security Administration vital status
files, and California state death certificate registry during
follow-up [18]. Case ascertainment was extremely reli-
able as the majority of events were captured within the
health delivery system. The number and type of events
were followed for the exposed group with CKD and the
unexposed control group without CKD from enrollment
until death, disenrollment or the end of the study period
on December 31, 2008 which was the latest date with
complete death information at the time of analysis. For
patients who had more than one event during the fol-
low-up period, the first outcome of its kind was
included in the results (e.g. the first occurrence of acute
myocardial infarction). Incidence rates were reported in
rates per 100 person-years for each event type.
Statistical approach
All analyses were performed using SAS statistical soft-
ware version 9.1 (Cary, N.C.). Differences between
patients with CKD and without CKD were compared
using Student’stt e s tf o rc o n t i n u o u sv a r i a b l e sa n dc h i -
squared test for categorical variables. We performed
Cox proportional hazards regression to examine the
association between level of pre-event kidney function
and the risk of recurrent cardiovascular disease event,
with eGFR ≥ 60 ml/min/1.73 m
2 as the referent level of
kidney function. Variables included in models were
based on variables that were significantly different
between study population and controls on bivariate ana-
lyses or have previously been shown to be associated
either with kidney function or cardiovascular disease.
Patient demographic characteristics, lifestyle factors and
comorbid conditions were added to regression models.
MPRs for statins, b-blockers, calcium channel blockers,
ACE inhibitors and ARBs were included in the final
model to evaluate whether post-event medication expo-
sure mediated the risk of recurrent cardiovascular events
or death in those with CKD.
Results
The study included 159 patients with CKD and 1088
patients without CKD before their incident CHD diag-
nosis. Patients with CKD were more likely than those
without CKD to be older and women (Table 1). Those
with CKD were less likely to engage in moderate or
heavy activities compared with the non-CKD group.
Mean eGFR was 49.7 ± 9.8 ml/min/1.73 m
2 for those
with CKD and 85.0 ± 17.7 ml/min/1.73 m
2 for those
without CKD.
Patients with pre-existing CKD were more likely than
those without CKD to have a history of stroke, diabetes
mellitus and hypertension. Mean body mass index was
similar in both groups (Table 1). CKD patients were
more likely to have elevated blood pressure compared
with patients who did not have CKD (Table 1).
At baseline, only 1.3% of patients with CKD were at
the current guideline-based target blood pressure
(defined as < 130/80 mm Hg for those with CKD or dia-
betes mellitus and < 140/90 mm Hg for all others) com-
pared with 1.8% of those without CKD. At the end of
the follow-up period, 30.2% of those with CKD were at
goal blood pressure compared with 19.2% in non-CKD
patients.
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1.9% of those without CKD. At the end of the follow-
up period, 30.2% of those with CKD achieved an LDL
< 70 mg/dL compared with 27.0% of those without
CKD.
At the end of the follow-up period, those with CKD
achieved a greater reduction in systolic and diastolic
Table 1 Baseline characteristics of ADVANCE subjects with incident coronary heart disease at enrollment by CKD status*
Characteristic CKD (N = 159) Non-CKD (N = 1088) P Value
Mean (SD) Age, year 66.8 (7.9) 61.7 (8.3) < 0.001
Women, % 42.8 25 < 0.001
African American 6.3 3.9
Mean (SD) prior estimated glomerular filtration rate (ml/min/1.73 m
2) 49.7 (9.8) 85 (17.7) < 0.001
Married/Domestic Partner 66.7 75.1 < 0.001
Current cigarette smoking, % 7.6 9.0 0.3
Alcohol use in prior 12 months, % 67.3 69.8 0.5
Leisure-time Activity in past 12 months, % 0.02
Minimal 42.8 31.0
Light 12.6 18.9
Moderate 31.5 35.8
Heavy 13.2 14.3
Medical History, %
Stroke/transient ischemic attack 17.0 9.4 < 0.001
Peripheral arterial disease 13.8 9.4 0.08
Diabetes mellitus 34.6 26.9 0.04
Diagnosed hypertension 90.6 79.5 < 0.001
Parental History of Coronary Disease, % 45.9 51.4 0.2
Sibling History of Coronary Disease, % 25.8 22.9 0.4
Mean systolic blood pressure (mm Hg) 132.0 122.0 < 0.001
Systolic (mm Hg), % < 0.001
≤ 120 31.7 52.2
121-129 19.0 18.7
130-139 16.5 13.1
140-159 19.0 12.3
160-179 11.4 2.8
> 180 2.5 1.0
Mean diastolic blood pressure (mm Hg) 73.0 71.1 0.02
Diastolic (mmHg), % < 0.001
≤ 80 81.5 84.7
81-84 6.4 8.5
85-89 4.5 4.1
90-99 4.5 2.6
100-109 1.9 0.2
≥ 110 1.3 0
Mean (SD) total cholesterol 215.2 (41.4) 214.9 (41.8) 0.9
Mean (SD) LDL cholesterol 126.9 (32.8) 131.7 (35.7) 0.2
Mean (SD) HDL cholesterol 47.2 (14.4) 44.5 (12.2) 0.02
Mean (SD) triglyceride level 201.2 (139.0) 200.4 (130.2) 0.9
Mean (SD) body mass index (kg/m
2) 29.6 (5.1) 29.1 (5.4) 0.4
*CKD indicates chronic kidney disease
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achieving an improvement of their lipid profiles over
time, with no significant difference between the CKD
and non-CKD group (Table 2).
Post-CHD event ACE inhibitor use was lower and cal-
cium channel blocker use was higher in those with CKD
versus those without CKD (Table 3). There were no sta-
tistically significant differences patients with and without
CKD in post-CHD event exposure to statins, b-blockers,
and ARBs (Table 3).
The crude incidence of any hospitalized recurrent car-
diovascular event (e.g., acute myocardial infarction,
angina, coronary revascularization, peripheral arterial
disease and stroke) and death were higher in CKD ver-
sus non-CKD patients (13.9 versus 11.5 per 100 person-
years respectively, P < 0.001) (Table 4). In patients with
C K D ,t h e r ew e r eat o t a lo f3 0 7t o t a le v e n t s( N=2 3
acute myocardial infarction, N = 32 angina, N = 98
revascularization, N = 51 percutaneous coronary inter-
vention, N = 53 coronary artery bypass surgery, N = 9
stroke, N = 5 peripheral vascular disease and N = 36
death) during follow-up. In patients without CKD, there
were a total of 1,808 events (N = 86 acute myocardial
infarction, N = 187 angina, N = 663 revascularization, N
= 446 percutaneous coronary intervention, N = 260 cor-
onary artery bypass surgery, N = 56 stroke, N = 17 per-
ipheral vascular disease and N = 93 death) during
follow-up.
Compared with eGFR ≥ 60 ml/min/1.73 m
2,t h o s ei n
lower eGFR categories had higher relative rates of recur-
rent cardiovascular events or death (Table 5). After
adjustment for patient characteristics (Model 2) and
comorbid conditions (Model 3), the hazard ratio for
recurrent cardiovascular event or death decreased for
eGFR 45-59 ml/min/1.73 m
2 and eGFR < 45 ml/min/
1.73 m
2. Finally, after further adjustment for statin, b-
blocker, calcium channel blocker, ACE inhibitor or
ARB, there were no longer significant associations for
eGFR 45-59 ml/min/1.73 m
2 or eGFR < 45 ml/min/1.73
m
2 (Table 5).
Discussion
Among a unique, well-characterized cohort of persons
with incident CHD, we evaluated whether differential
cardiovascular medication use may explain, at least in
part, the excess risk of recurrent cardiovascular disease
events and death in CKD patients with incident CHD.
We found that in adults with newly recognized CHD,
those with pre-existing CKD were less likely to receive
post-event ACE inhibitors and more likely to receive
calcium channel blockers. Blood pressure and lipid
levels improved in those with CKD during the follow-up
period suggesting that study participants were aggres-
sively treated and doses were optimized in those who
did receive treatment. Mild (eGFR 45-59 ml/min/1.73
m
2) and moderate (eGFR < 45 ml/min/1.73 m
2)C K D
Table 2 Change in cardiovascular risk factors from baseline to end of follow-up period by CKD status*
Characteristic CKD
(N = 159)
Non-CKD
(N = 1088)
P Value
Systolic blood pressure, mean (SD) (mm Hg) -2.4 (22.9) 3.2 (21.2) 0.01
Diastolic blood pressure, mean(SD) (mm Hg) -2.9 (13.2) 0.36 (11.6) < 0.001
Total cholesterol, mean (SD) (mg/dL) -55.9 (50.5) -54.7 (43.8) 0.7
LDL cholesterol, mean (SD) (mg/dL) -44.3 (39.9) -46.3 (37.1) 0.6
HDL cholesterol, mean (SD) (mg/dL) 0.22 (11.7) 0.94 (9.9) 0.5
Triglycerides, mean (SD) (mg/dL) -37.5 (114.4) -47.4 (120.2) 0.4
*CKD indicates chronic kidney disease
Table 3 Post-coronary heart disease event exposure of cardiovascular medications by CKD status*
Medication Class CKD (N = 159)
Medication Possession Ratio (SD)
Non-CKD (N = 1088)
Medication Possession Ratio (SD)
P Value
Statin 0.82 (0.25)
N = 155
0.79 (0.27)
N = 1034
0.3
b-blockers 0.78 (0.30)
N = 146
0.74 (0.3)
N = 1026
0.2
Calcium channel blockers 0.47 (0.38)
N=8 0
0.39 (0.37)
N = 350
0.06
Angiotensin converting enzyme inhibitors 0.50 (0.39)
N = 137
0.58 (0.38)
N = 874
0.03
Angiotensin receptor blockers 0.50 (0.35)
N=3 6
0.52 (0.34)
N = 203
0.8
*CKD indicates chronic kidney disease
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events and death even after adjustment for patient char-
acteristics, but this association was no longer significant
and had estimates near the null after additional adjust-
ment for post-event cardiovascular medication use.
These results suggest that the excess risk of recurrent
cardiovascular events and death in patients with CKD
may be explained, in part, by the differential use of car-
diovascular medications. To our knowledge, no pre-
viously published study has examined whether
differential medication exposure can explain the excess
burden of recurrent cardiovascular disease in CKD
patients with known CHD.
In our study, the overall improvement in blood pres-
sure and lipid levels in those with CKD from baseline to
the end of follow-up suggests that those who were trea-
ted with cardiovascular medications were treated aggres-
sively. However, we found that those with CKD were
less likely to receive ACE inhibitors which may be a
reflection of concern of drug-related adverse effects,
such as hyperkalemia or a hemodynamically mediated
decrease in eGFR. The non-significant difference
Table 4 Incidence (per 100 person-years) of recurrent cardiovascular events and death by CKD status*
Cardiovascular Event CKD (N = 159)
Rate per 100 person years
(95% Confidence Interval)
Non- CKD (N = 1088)
Rate per 100 person years
(95% Confidence Interval)
Acute myocardial Infarction 1.75 (1.10 to 2.62) 0.87 (0.70 to 1.08)
Angina 2.44 (1.67 to 3.45) 1.96 (1.69 to 2.26)
Any revascularization 10.15 (8.42 to 12.37) 9.58 (8.87 to 10.34)
Percutaneous coronary intervention 4.25 (3.17 to 5.60) 5.50 (5.01 to 6.04)
Coronary artery bypass surgery 4.48 (3.35 to 5.86) 2.89 (2.54 to 3.26)
Stroke 0.63 (0.29 to 1.21) 0.55 (0.42 to 0.71)
Peripheral arterial disease 0.35 (0.11 to 0.82) 0.16 (0.10 to 0.26)
Death 2.51 (1.76 to 3.47) 0.89 (0.73 to 1.10)
Any Event 13.89 (11.60 to 16.51) 11.47 (10.68 to 12.32)
*CKD indicates chronic kidney disease
Table 5 Hazard ratio of recurrent cardiovascular event or death in ADVANCE cohort by eGFR (ml/min/1.73 m
2)*
Hazard ratio (95% CI) of recurrent
cardiovascular event or death
Model 1: Unadjusted Model
eGFR > 60 Referent
eGFR 45-59 1.61 (1.18 to 2.18)
eGFR < 45 1.85 (1.19 to 2.89)
Model 2: Adjusted for age, sex, race/ethnicity, smoking, alcohol use, and physical
activity
eGFR > 60 Referent
eGFR 45-59 1.52 (1.11 to 2.10)
eGFR < 45 1.70 (1.10 to 2.67)
Model 3: Model 2 + adjusted for body mass index and history of diabetes and
hypertension
eGFR > 60 Referent
eGFR 45-59 1.47 (1.10 to 2.02)
eGFR < 45 1.58 (1.00 to 2.50)
Model 4: Model 3 + medication possession ratio of statins, b-blockers, calcium channel
blockers, ACE inhibitors
†/ARBs
‡
eGFR > 60 Referent
eGFR 45-59 0.82 (0.25 to 2.66)
eGFR < 45 1.19 (0.25 to 5.58)
*eGFR indicates glomerular filtration rate
†ACE inhibitor indicates angiotensin converting enzyme inhibitor
‡ARB indicates angiotensin receptor blocker
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versus those without CKD may be explained by the low
overall use of ARBs in our sample. We observed no sig-
nificant differences in the post-event receipt of statins
and b-blockers between patients with or without pre-
existing CKD which is consistent with aggressive sec-
ondary prevention efforts among all patients within this
health care setting. The higher use of calcium channel
blockers among those with CKD is consistent with the
fact that it is often more difficult to control blood pres-
sure among CKD patients.
Several studies have found that selected cardiovascular
medications appear to be beneficial in patients with
CKD. The Study of Heart and Renal Protection
(SHARP) randomly assigned patients with advanced
CKD or ESRD to ezetimibe plus simvastatin and found
a reduction in LDL cholesterol levels as well as a reduc-
tion in cardiovascular events with this combination ther-
apy compared with placebo [32]. Several observational
studies as well have observed lower rates of cardiovascu-
lar outcomes in those with known CHD and CKD who
received statin therapy [33-36]. In a post hoc analysis of
the Heart Outcomes Prevention Evaluation (HOPE
trial), ramipril was associated with a lower incidence of
subsequent cardiovascular events in both mild CKD and
non-CKD patients [37]. In the Survival And Ventricular
Enlargement (SAVE) trial, post-myocardial randomiza-
tion to captopril resulted in a reduction of cardiovascu-
lar events, regardless of renal function [38]. In contrast,
a study of more than 6,000 heart failure patients with
varying levels of renal function found that while users of
ACE inhibitors without CKD had lower mortality com-
pared with those who did not receive ACE inhibitor
therapy, receipt of ACE inhibitors was not associated
with mortality differences in the subset of patients with
CKD (adjusted OR 1.21, 95% CI 0.97 to 1.51) [39]. How-
ever, the study participants had low ejection fraction,
were followed for only 12 months and the study did not
focus on incident ACE inhibitor therapy, raising the
possibility of reverse causality or the presence of resi-
dual confounders (e.g. anemia, as hemoglobin data was
not available). Studies have also found a survival benefit
with b-blocker use in ESRD [40] and CKD [41]. The
Bezafibrate Infarction Prevention (BIP) study found that
in a cohort of 568 CKD patients with CHD, 43.1% used
beta-blockers at baseline and use of beta-blockers was
associated with a reduction of the rate of acute myocar-
dial infarction or sudden cardiac death [41]. Our study
is consistent with these results and extends our knowl-
edge by also studying the influence of other commonly
prescribed cardiovascular medications within a diverse,
community-based sample of newly diagnosed CHD.
While previous studies have examined the use of a sin-
gle cardiovascular medication, we were able to study
multiple cardiovascular medications that are commonly
prescribed together.
Our study had several strengths. Our study population
was a large and diverse sample of well-characterized
patients. We had up to seven years of longitudinal data
on medication use for the study population and were
able to accurately calculate a medication possession
ratio. Our study had a few limitations as well. Informa-
tion on longitudinal use of aspirin was unavailable in
our study population. We also could not completely
account for potential confounding by indication for
selected medications. For example, we could not control
for clinical decisions such as withholding an ACE inhibi-
tor in a patient with hyperkalemia. As with any observa-
tional study, we cannot prove the causal role of post-
event medication use on recurrent cardiovascular out-
comes, but we attempted to control for known major
confounders and found that the unfavorable association
between pre-existing CKD and outcomes was no longer
significant after adjustment for post-event receipt of car-
diovascular medications. Finally, we conducted our
study among health plan members within a large inte-
grated health care delivery system in northern Califor-
nia, so our findings may not be completely generalizable
to other health care settings or to uninsured patients.
Conclusions
In conclusion, our study suggests that differential cardi-
ovascular medication use after an incident coronary
heart disease event may explain, at least in part, the
excess risk of recurrent cardiovascular events and death
in patients with pre-existing chronic kidney disease.
Although further randomized trials are needed to
explore this association, our results suggest that patients
with chronic kidney disease are at high risk for recur-
rent cardiovascular events and death and that more sys-
tematic use of selected cardiovascular medication may
help to significantly attenuate this risk.
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